|
Diabetes Medication Article
Background Information about Insulin
When we eat, our bodies break food down into organic compounds, one of
which is glucose.
The cells of our bodies use glucose as a source of energy for movement,
growth, repair, and other functions. But before the cells can use glucose,
it must move from the bloodstream into the individual cells. This process
requires insulin.
Insulin is produced by the beta cells in the islets of Langerhans in the pancreas. When glucose enters our blood, the pancreas should automatically produce the right amount of insulin to move glucose into our cells. People with type 1 diabetes produce no insulin. People with type 2 diabetes do not always produce enough insulin.
Diabetes Testing Center
Heart News Center
Hot Home Gym Reviews
The Secret Wisdom You Have Inside
Get Rid of Your Belly fat
Byetta Drug News
Byetta Drug
IMPORTANT: Bing News RSS feed has moved!
However, a further payment of $250 million to Lilly over a lawsuit Amylin had launched over Lilly's collaboration with German drug manufacturer Boehringer Ingelheim comes at a pivotal time for Amylin. The Byetta manufacturer is losing money. Last year ...
Read moreByetta Manufacturer Reportedly at a Crossroads
Amylin took a larger quarterly loss because of the end of its development and marketing partnership with Eli Lilly and Co. The company reported greater marketing and research and development costs, and sales of its older drug Byetta also decreased.
Read moreAmylin takes bigger 1Q loss after Lilly deal ends
The move by Amylin, which has attracted attention for its diabetes drugs Bydureon and Byetta, comes as the company is under pressure from the activist investor Carl C. Icahn. Mr. Icahn has urged Amylin to seek a buyer and has threatened to run a ...
Read moreAmylin Is Said to Pursue a Sale
How so? Well, Bydureon is taking market share from the older Amylin drug called Byetta – Bydureon is a longer-acting version – and Bydureon prescriptions are, in fact, rising, but still behind the pace that Victoza registered following its ...
Read moreThe Amylin Mystery And Bydureon Sales
There have been concerns about pancreatitis with GLP-1 analogs for a long time now and many of the same concerns were expressed by Amylin's first drug Byetta and its new drug Bydureon. Unfortunately for the petitioners, this is an issue more interesting to ...
Read moreWill Amylin Stand To Gain From A Citizen's Petition Challenging Victoza?
In 2009, the FDA ruled that such drugs must be labelled with a warning about pancreatitis; Victoza carries that warning, as do Byetta and Bydureon, formulations of the GLP-1 mimic exenatide, made by Amylin Pharmaceuticals of San Diego, California.
Read moreDebate on diabetes drugs gathers pace
He filed a lawsuit against the San Diego company in Delaware court. Amylin, which sells the diabetes drugs Bydureon and Byetta, said the lawsuit is "without merit." It said the company is aware of its fiduciary responsibilities and is committed ...
Read moreIcahn sues Amylin in effort to shake up board
Amylin is looking to return Byetta to growth now that it is armed with FDA approval for the use of the drug as a first-line monotherapy for type II diabetes patients. Byetta should also benefit from the recent approval under which it can be used in ...
Read moreWider Loss at Amylin
Officials of San Diego-based Amylin, make of the diabetes drugs Bydureon and Byetta, said they were pleased with Icahn’s decision to drop the bylaw suit. The company’s board “continually considers all options available and is relentlessly ...
Read more